Fox Chase Cancer Center News

PHILADELPHIA (July 22, 2021)—In a study published today in JAMA Oncology, researchers at Fox Chase Cancer Center found that the odds of a patient undergoing prostate cancer surgery were lower among Black patients compared with white patients during the initial wave of the COVID-19 pandemic.

PHILADELPHIA (July 22, 2021)—Charline Ogier, PhD, a postdoctoral researcher at Fox Chase Cancer Center, was recently awarded a fellowship from the Pancreatic Cancer Action Network (PanCAN) to continue her work in advancing pancreatic cancer therapies.

PHILADELPHIA (July 22, 2021)—Ralph Francescone, PhD, a researcher at Fox Chase Cancer Center, was recently awarded a grant from the Pancreatic Cancer Action Network (PanCAN) to continue his work in advancing pancreatic cancer therapies.

PHILADELPHIA (July 20, 2021) – Fox Chase Cancer Center is pleased to announce the hiring of Zachary Frosch, MD, MSHP, who will join the Department of Hematology/Oncology as an assistant professor.

PHILADELPHIA (July 20, 2021)—Delinda Pendleton, BSN, MSN, a long-time employee at Fox Chase Cancer Center, has been named a Planetree Fellow in Person-Centered Care. The fellows program is operated by Planetree International, a leading person-centered care advocacy and standard setting organization.

PHILADELPHIA (July 13, 2021)—Researchers at Fox Chase Cancer Center have recently shown that sonic hedgehog-driven (SHH) medulloblastoma relapse may be prevented by targeting the transdifferentiation—a cell’s ability to convert from one type of cell to another—of astrocytes.

PHILADELPHIA (July 13, 2021)—Researchers at Fox Chase Cancer Center have received a grant to study how stem cells in the ovary respond to nutrition, particularly in ways that mirror certain cancers.

PHILADELPHIA (July 13, 2021)– Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Fox Chase Cancer Center in Philadelphia, PA, has been added as an active trial site for the dose-expansion stage of the ongoing clinical trial evaluating the company’s lead drug candidate, seclidemstat, in patients with relapsed or refractory Ewing sarcoma and advanced FET-rearranged sarcomas.